Cancer Control. 2000;7(5) 

Introduction

  • LAC-USC-3P941A, NCI-V97-1339 Phase II Diagnostic Study of Laparoscopy With Laparoscopic Ultrasound in Pancreatic Cancer

    Chairperson: Dilip Parekh. Telephone: 213-342-5837. Lead organization: USC/Norris Comprehensive Cancer Center. Age range: Over 18.

  • NU-98CC2, NCI-G00-1703 Phase I/II Pilot Study of Enteral Wall-stents in Patients With Duodenal Obstruction Secondary to Malignancy

    Chairperson: Willis Parsons, III. Telephone: 312-695-4028. Lead organization: Robert H. Lurie Comprehensive Cancer Center, Northwestern University. Age range: 18 and over.

  • NU-97X1, NCI-G00-1685 Phase II Study of Octreotide as Palliative Therapy for Inoperable Bowel Obstruction Secondary to Cancer

    Chairperson: J. Cameron Muir. Telephone: 312-908-5250. Lead organization: Robert H. Lurie Comprehensive Cancer Center, Northwestern University. Age range: Over 18.

  • CPMC-IRB-8544, NCI-V99-1538 Phase III Study of Gemcitabine Versus Intensive Pancreatic Proteolytic Enzyme Therapy With Ancillary Nutritional Support in Patients With Stage II, III, or IV Adenocarcinoma of the Pancreas

    Chairperson: John Chabot. Telephone: 212-305-9468. Lead organization: Herbert Irving Comprehensive Cancer Center. Age range: 18 to physiologic 65.

  • NCCTG-964352 Phase I Study of Gemcitabine, Cisplatin, and Radiation Therapy in Patients With Unresectable or Locally Recurrent Pancreatic and Gastric Cancer

    Chairperson: James A. Marten-son, Jr. Telephone: 507-284-4561. Lead organization: North Central Cancer Treatment Group. Age range: 18 and over.

  • PCI-97-108, NCI-T97-0109 Phase I Study of the Radiosensitizer Gadolinium Texaphyrin With Concurrent Radiotherapy in Patients With Advanced Biliary Tree or Pancreatic Cancer

    Chairperson: Ramesh Rama-nathan. Telephone: 412-648-6507. Lead organization: University of Pittsburgh Cancer Institute. Age range: 18 and over.

  • MSKCC-98019, NCI-H98-0020 Phase I Study of Gemcitabine in Combination With Radiation Therapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma

    Chairperson: David Paul Kelsen. Telephone: 212-639-2933. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.

  • NYU-9703, NCI-G98-1423 Phase I/II Study of Gemcitabine and Cisplatin Followed by Combined Chemoradiation and/or Surgical Resection in Patients With Locally Advanced Pancreatic Cancer

    Chairperson: Howard S. Hochster. Telephone: 212-652-1912. Lead organization: Kaplan Cancer Center. Age range: 18 and over.

  • NCCTG-984351 Phase I/II Study of Gemcitabine Plus Oxaliplatin in Patients With Refractory Locally Advanced or Metastatic Pancreatic Carcinoma

    Chairperson: Steven R. Alberts. Telephone: 507-284-4918. Lead organization: North Central Cancer Treatment Group. Age range: 18 and over.

  • CMMI-C-033-98, NCI-H99-0042, NCI-V99-1571 Phase I/II Study of High Dose Radioimmuno-therapy With Yttrium Y 90 Anti-CEA Monoclonal Antibody MN-14 Plus Autologous Peripheral Blood Stem Cell Rescue in Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer

    Chairperson: Malik Juweid. Telephone: 973-844-7115. Lead organization: Garden State Cancer Center. Age range: 18 and over.

  • EORTC-40984 Phase II Randomized Study of Docetaxel and Gemcitabine Versus Docetaxel and Cisplatin in Metastatic or Locoregionally Advanced Pancreatic Carcinoma

    Chairperson: Manfred Lutz. Telephone: 0049-731-502-01 (Ger-many). Lead organization: EORTC Gastrointestinal Tract Cancer Group. Age range: 18 and over.

  • EORTC-16994P, ASTA-D-19575-3166 Phase II Randomized Study of Glufosfamide With or Without Hydration in Patients With Advanced Pancreatic Cancer

    Chairperson: Nicholas A. Pavlidis. Telephone: 30-651-99394 (Greece). Lead organization: EORTC Early Clinical Studies Group. Age range: 18 and over.

  • SVMC-ONC-222P, NCI-V96-0886 Phase II Study of Active Intralymphatic Immunotherapy With IFN-A-Treated Allogeneic Tumor Cells Plus GM-CSF and CTX for Advanced Pancreatic Adenocarcinoma

    Chairperson: Charles Wiseman. Telephone: 213-484-7575. Lead organization: St. Vincent Medical Center - Los Angeles. Age range: 18 and over.

  • BRI-PA-2 Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Stage IV Adenocarcinoma of the Pancreas

    Chairperson: Stanislaw R. Burzynski. Telephone: 713-335-5697. Lead organization: Burzynski Research Institute. Age range: 18 and over.

  • DUMC-97093, NCI-G98-1457 Phase II Study of Carcinoembryonic Antigen (CEA) Peptide Pulsed Dendritic Cells in Patients With Resected Stage I, II, and III Adenocarcinoma of the Pancreas Expressing CEA

    Chairperson: Michael A. Morse. Telephone: 919-681-3480. Lead organization: Duke Comprehensive Cancer Center. Age range: 18 and over.

  • MDA-DM-98071, NCI-T98-0028 Phase II Study of Dolastatin 10 in Patients With Metastatic Pancreatic Adenocarcinoma

    Chairperson: Robert A. Wolff. Telephone: 713-792-2828. Lead organization: University of Texas --MD Anderson Cancer Center. Age range: 18 and over.

  • SWOG-9700 Phase II Study of Fluorouracil, Leucovorin, Mitomycin and Dipyridamole in Patients With Locally Advanced Unresected Pancreatic Adeno-carcinoma

    Chairperson: William H. Isacoff. Telephone: 310-824-4133. Lead organization: Southwest Oncology Group. Age range: not specified.

  • BRUOG-PA-77, NCI-T98-0067 Phase II Study of Gemcitabine and Trastuzumab (Herceptin) in Patients With Metastatic Pancreatic Cancer and Overexpression of HER2-Neu

    Chairperson: Howard Safran. Telephone: 401-793-7151. Lead organization: Brown University Oncology Group. Age range: Over 18.

  • WSU-D-1993, NCI-G99-1553, WSU-04-03-99-M01-FB Phase II Study of Gemcitabine, Cisplatin, and Fluorouracil in Patients With Unresectable Stage III or IV Pancreatic Adenocarcinoma

    Chairperson: Philip A. Philip. Telephone: 313-745-9155. Lead organization: Barbara Ann Karmanos Cancer Institute. Age range: Adult.

  • CMM-95079, NCI-V95-0760, CH/UMC-95079 Phase II Study of Interstitial Colloidal Phosphorus

    P32 Integrated into the Treatment of Patients With Unresectable Pancreatic Cancer

    Chairperson: Stanley E. Order. Telephone: 516-222-2727. Lead organization: Center for Molecular Medicine. Age range: 18 and over.

  • UAB-9915, NCI-G00-1730, ISIS-2503-CS5, UAB-F990526011 Phase II Study of ISIS 2503 in Patients With Advanced Adeno-carcinoma of the Pancreas

    Chairperson: James Posey, III. Telephone: 205-934-0916. Lead organization: University of Alabama Comprehensive Cancer Center. Age range: 18 and over.

  • IUMC-9710-07, NCI-T98-0046 Phase II Study of Perillyl Alcohol in Patients With Resectable, Stage II or Stage III Pancreatic Adeno-carcinoma

    Chairperson: Patrick J. Loehrer, Sr. Telephone: 317-278-7418. Lead organization: Indiana University Cancer Center. Age range: 18 and over.

  • SWOG-S9924 Phase II Study of R115777 in Patients With Advanced Adenocarcinoma of the Pancreas

    Chairperson: Charles A. Colt-man, Jr. Telephone: 210-616-5580. Lead organization: Southwest Oncology Group. Age range: Not specified.

  • FCCC-00005, NCI-45 Phase II Study of R115777 in Patients With Metastatic Pancreatic Cancer

    Chairperson: Neal Jay Meropol. Telephone: 215-728-2450. Lead organization: Fox Chase Cancer Center. Age range: 18 and over.

  • PD-994-011, ILEX-994-011 Randomized, Double Blind, Placebo-Controlled, Multicenter Study of CI-994 Capsules Plus Gemcitabine Infusion Versus Placebo Capsules Plus Gemcitabine Infusion in the Treatment of Patients With Advanced Pancreatic Cancer

    Chairperson: Kathy M. Diener. Telephone: 734-622-1985. Lead organization: Parke-Davis Pharmaceutical Research. Age range: 18 and over.

  • EORTC-05962 Phase III Randomized Multicenter Trial of Infusional Fluorouracil With or Without Cisplatin and With or Without Chronomodulation Against Locally Advanced or Metastatic Pancreatic Cancer

    Chairperson: Francis Levi. Telephone: 33-1-45-59-35-14 (France). Lead organization: EORTC Chrono-therapy Study Group. Age range: 18 to 75.

  • JRF-R115777-INT-11 Phase III Randomized Study of Gemcitabine With or Without R115777 in Patients With Advanced Pancreatic Cancer

    Contact: Patient Referral Janssen Research Foundation. Telephone: 888-773-9831. Lead organization: Janssen Research Foundation. Age range: 18 and over.

  • SUPERGEN-RFS2000-06, PCI-99- 001 Phase III Randomized Study of Nitrocamptothecin Versus Fluorouracil in Patients With Recurrent or Refractory Pancreatic Cancer Chairperson: Randee Rolens. Telephone: 925-327-0200. Lead organization: SuperGen, Inc. Age range: Over 18.

  • SUPERGEN-RFS2000-02 Phase III Randomized Study of Oral Nitrocamptothecin vs Gemcitabine in Chemotherapy Naive Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Pancreas

    Chairperson: Randee Rolens. Telephone: 925-327-0200. Lead organization: SuperGen, Inc. Age range: Over 18.

  • SUPERGEN-RFS2000-09 Phase III Randomized Study of Oral Nitrocamptothecin vs Most Appropriate Chemotherapy in Patients With Recurrent or Refractory Adenocarcinoma of the Pancreas

    Chairperson: Randee Rolens. Telephone: 925-327-0200. Lead organization: SuperGen, Inc. Age range: Over 18.

  • MAYO-974301, NCI-G97-1302 Phase III Randomized Study of Pancreatoduodenectomy With or Without Extended Lymphadenectomy Followed by Chemoradiation Therapy for Resectable Pancreatic Adeno-carcinoma

    Chairperson: Richard M. Goldberg. Telephone: 507-266-0029. Lead organization: Mayo Clinic Cancer Center. Age range: 18 and over.

  • RTOG-9704 Phase III Study of Adjuvant Fluorouracil Chemoradiation Preceded and Followed by Fluorouracil or Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma

    Chairperson: William F. Regine. Telephone: 606-323-6486. Lead organization: Radiation Therapy Oncology Group. Age range: 18 and over.

ASTA = ASTA Medica
BRI = Burzynski Research Institute
BRUOG = Brown University Oncology Group
CMMI = Center for Molecular Medicine and Immunology
CPMC = Columbia Presbyterian Medical Center
DUMC = Duke Comprehensive Cancer Center
EORTC = European Organization for Research on Treatment of Cancer
FCCC = Fox Chase Cancer Center
ILEX = ILEX Oncology, Inc
IUMC = Indiana University Medical Center
JRF = Janssen Research Foundation
LAC-USC = University of Southern California
MAYO = Mayo Clinic Cancer Center
MDA = M.D.Anderson Cancer Center
MSKCC = Memorial Sloan-Kettering Cancer Center
NCCTG = North Central Cancer Treatment Group
NU = Robert H. Lurie Comprehensive Cancer Center, Northwestern University
NYU = New York University Cancer Center
PCI = University of Pittsburgh Cancer Institute
PD = Parke-Davis Pharmaceutical Research
RTOG = Radiation Therapy Oncology Group
SUPERGEN = SuperGen, Inc
SVMC = St.Vincent Medical Center
SWOG = Southwest Oncology Group
UAB = University of Alabama Comprehensive Cancer Center
WSU = Wayne State University

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....